Cargando…

DNA damaging agents in ovarian cancer

Epithelial ovarian cancer (EOC) is very sensitive to upfront chemotherapy. This condition is attributable to defects in the DNA damage repair system. Agents that damage DNA are the main drugs used for its treatment. Many EOC cells have DNA repair deficiencies that confer susceptibility to these agen...

Descripción completa

Detalles Bibliográficos
Autor principal: Barretina-Ginesta, Maria-Pilar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7573464/
https://www.ncbi.nlm.nih.gov/pubmed/33240444
http://dx.doi.org/10.1016/j.ejcsup.2020.06.001
_version_ 1783597445378211840
author Barretina-Ginesta, Maria-Pilar
author_facet Barretina-Ginesta, Maria-Pilar
author_sort Barretina-Ginesta, Maria-Pilar
collection PubMed
description Epithelial ovarian cancer (EOC) is very sensitive to upfront chemotherapy. This condition is attributable to defects in the DNA damage repair system. Agents that damage DNA are the main drugs used for its treatment. Many EOC cells have DNA repair deficiencies that confer susceptibility to these agents. Platinum is the most important agent for first-line and also for relapses, together with other drugs that can be given as monotherapy or along with platinum or other drugs. Lately, the emerging role of PARP inhibitors has changed the landscape of opportunities for patients with EOC. All these strategies will be reviewed in this article.
format Online
Article
Text
id pubmed-7573464
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-75734642020-11-24 DNA damaging agents in ovarian cancer Barretina-Ginesta, Maria-Pilar EJC Suppl Article Epithelial ovarian cancer (EOC) is very sensitive to upfront chemotherapy. This condition is attributable to defects in the DNA damage repair system. Agents that damage DNA are the main drugs used for its treatment. Many EOC cells have DNA repair deficiencies that confer susceptibility to these agents. Platinum is the most important agent for first-line and also for relapses, together with other drugs that can be given as monotherapy or along with platinum or other drugs. Lately, the emerging role of PARP inhibitors has changed the landscape of opportunities for patients with EOC. All these strategies will be reviewed in this article. Elsevier 2020-08-22 /pmc/articles/PMC7573464/ /pubmed/33240444 http://dx.doi.org/10.1016/j.ejcsup.2020.06.001 Text en © 2020 Published by Elsevier Ltd. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Article
Barretina-Ginesta, Maria-Pilar
DNA damaging agents in ovarian cancer
title DNA damaging agents in ovarian cancer
title_full DNA damaging agents in ovarian cancer
title_fullStr DNA damaging agents in ovarian cancer
title_full_unstemmed DNA damaging agents in ovarian cancer
title_short DNA damaging agents in ovarian cancer
title_sort dna damaging agents in ovarian cancer
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7573464/
https://www.ncbi.nlm.nih.gov/pubmed/33240444
http://dx.doi.org/10.1016/j.ejcsup.2020.06.001
work_keys_str_mv AT barretinaginestamariapilar dnadamagingagentsinovariancancer